Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have received an average recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $8.50.

A number of equities analysts have recently issued reports on the company. Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Monday. Finally, Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a research note on Tuesday. They set a “buy” rating and a $3.00 price target on the stock.

Institutional Trading of NeuroSense Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics during the third quarter valued at about $26,000. Jane Street Group LLC purchased a new stake in NeuroSense Therapeutics during the 2nd quarter valued at about $54,000. Yorkville Advisors Global LP bought a new position in NeuroSense Therapeutics during the 4th quarter worth approximately $77,000. Finally, Squarepoint Ops LLC increased its stake in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the period. 1.04% of the stock is currently owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Price Performance

NRSN opened at $0.85 on Tuesday. The business’s fifty day simple moving average is $0.93 and its 200 day simple moving average is $1.03. NeuroSense Therapeutics has a 52 week low of $0.68 and a 52 week high of $2.60.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.